Viking Therapeutics (VKTX) is up 4.2% today at $41.19, extending recent gains. - The continued momentum follows the company's announcement last week (June 24, 2026) of the initiation of a Phase 1 study for VK3019, an experimental dual amylin and calcitonin receptor agonist for weight loss. - Analysts maintain broadly bullish price targets, reinforcing investor optimism in Viking's expanding obesity pipeline.